The Chiesi Group
GSK to expand respiratory pipeline with $1.4bn Aiolos Bio acquisition
The deal includes a monoclonal antibody ready to enter phase 2 development for asthma
Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease
About 300,000 people in the US have uncontrolled COPD and type 2 inflammation
WHO publishes new infodemic management tools for pandemic preparedness
The taxonomy will support pandemic planning for respiratory pathogen disease events
Chiesi Group and Affibody AB partner on respiratory disease treatments
The companies will progress up to three programmes against undisclosed target